Skip to main content
RENHE PHARMACY CO.,LTD logo

RENHE PHARMACY CO.,LTD — Investor Relations & Filings

Ticker · 000650 ISIN · CNE000000NF8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,739 across all filing types
Latest filing 2026-04-23 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 000650

About RENHE PHARMACY CO.,LTD

https://www.renheyaoye.com

Renhe Pharmacy Co., Ltd. specializes in the research, development, manufacturing, and distribution of pharmaceutical products and health-related commodities. The company maintains a diverse portfolio encompassing over-the-counter (OTC) medications, traditional Chinese medicines (TCM), health supplements, and personal care items. Its core product lines address various therapeutic areas, including respiratory health, digestive disorders, gynecology, and pediatrics. Renhe is recognized for its established brand equity, operating well-known labels such as Renhe, Youka, and Fuyan. The company integrates modern pharmaceutical technology with traditional medicinal practices to produce high-quality healthcare solutions. Its operations are supported by a comprehensive supply chain and an extensive marketing network, focusing on providing accessible healthcare products to a broad consumer base.

Recent filings

Filing Released Lang Actions
公司续聘2026年度审计机构的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the reappointment of the auditing firm for the fiscal year 2026. It details the auditor's qualifications, personnel, independence, and the board's approval process. It does not contain any financial statements or audit results but rather informs shareholders and the public about the proposed auditor appointment. The document length is short (2489 characters) and it is clearly an announcement about the audit firm engagement, not the audit report itself. Therefore, it fits the category of Audit Report / Information (AR) as it relates to audit matters but is not a full annual report or audit report containing financial data. However, since it is about the appointment of the audit firm and not the audit report or results, it is best classified as Audit Report / Information (AR).
2026-04-23 Chinese
国泰海通证券股份有限公司关于仁和药业股份有限公司2025年度募集资金存放与实际使用情况的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from a securities company acting as a sponsor institution, providing an audit opinion on the storage and actual use of funds raised by Renhe Pharmaceutical Co., Ltd. for the fiscal year 2025. It includes extensive financial data on the amount of funds raised, usage, investment projects, changes in investment projects, compliance with regulatory requirements, and the sponsor's verification opinion. The document references regulatory approvals, specific financial figures, and compliance with securities laws and stock exchange rules. It is not a brief announcement or a certification letter but a comprehensive report on the use of raised funds, which aligns with the category of Audit Report / Information (AR).
2026-04-23 Chinese
仁和药业股份有限公司年度募集资金存放、管理与使用情况专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "募集资金存放、管理与使用情况专项报告" which translates to a "Special Report on the Deposit, Management and Use of Raised Funds" for the year 2025 by Renhe Pharmaceutical Co., Ltd. It references regulatory requirements from the China Securities Regulatory Commission and Shenzhen Stock Exchange, and details the issuance of shares, the amount of funds raised, their management, usage, and project investment details. The document includes detailed financial figures on fundraising, usage, project progress, and changes in investment projects. It is a comprehensive report focused on the management and use of capital raised through a non-public stock issuance. This fits the definition of a Capital/Financing Update (CAP) as it provides updates on company fundraising, financing activities, and capital structure changes. It is not an announcement of a report (RPA), nor a full annual or interim report, nor a regulatory filing or other category. The document length is substantial and contains detailed financial data and analysis related to capital raised and its use. Therefore, the appropriate classification is CAP with high confidence.
2026-04-23 Chinese
内部控制审计报告-德皓内字[2026]00000065
Audit Report / Information Classification · 95% confidence The document is titled '内部控制审计报告' which translates to 'Internal Control Audit Report' and is issued by a certified public accounting firm. It specifically addresses the audit of the company's internal control over financial reporting as of December 31, 2025. The content includes the auditor's responsibility, the company's responsibility, and an audit opinion on the effectiveness of internal controls. There is no indication that this is a full annual report or a financial statement report, but rather a standalone audit report focused on internal controls. The document length is 3593 characters, which is consistent with a standalone audit report rather than a brief announcement or a full annual report. Therefore, the document fits the category of Audit Report / Information (AR).
2026-04-23 Chinese
关于授权董事会制定2026年中期分红方案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement from a company regarding the authorization of the board to formulate a 2026 interim dividend plan. It details the conditions, timing, and authorization scope for the mid-year dividend but does not contain actual financial statements or results. The document is relatively short (1303 characters) and serves as a formal notice about dividend planning and board authorization rather than a report or financial statement. Therefore, it fits best under the category of Notice of Dividend Amount (DIV), as it announces dividend-related plans and authorizations.
2026-04-23 Chinese
关于2025年度计提资产减值准备的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Renhe Pharmaceutical Co., Ltd. regarding the provision for asset impairment for the fiscal year 2025. It details the reasons, amounts, and types of asset impairment provisions (inventory, construction in progress, intangible assets, goodwill) and their impact on the company's financials. The document references accounting standards and includes independent directors' opinions on the reasonableness of the impairment. The document length is 3035 characters, which is relatively short and reads like an announcement rather than a full financial report. It does not contain full financial statements or comprehensive financial analysis but rather a specific disclosure about asset impairment provisions. This fits best with a Regulatory Filings (RNS) category, as it is a regulatory announcement about accounting estimates and provisions, not a full Annual Report (10-K) or Interim Report (IR).
2026-04-23 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.